Evidence map›Paper›PMID 38858522›Full record

Trial reportInternational journal of geriatric psychiatry2024

Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial).

Lijuan Zeng, Jamie Perin, Alden L Gross, David Shade, Krista L Lanctôt, Alan J Lerner, Jacobo E Mintzer, Olga Brawman-Mintzer, Prasad R Padala, Christopher H van Dyck and 5 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of geriatric psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lijuan ZengDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-4994-3275
Jamie PerinGlobal Disease Epidemiology and Control, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Alden L GrossDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
David ShadeDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Krista L LanctôtDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0001-7024-6637
Alan J LernerUniversity Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Jacobo E MintzerRalph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, South Carolina, USA.
Olga Brawman-MintzerRalph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, South Carolina, USA.
Prasad R PadalaCentral Arkansas Veterans Healthcare System, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Christopher H van DyckYale School of Medicine, New Haven, Connecticut, USA.
Anton P PorsteinssonUniversity of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Suzanne CraftWake Forest University, Winston-Salem, North Carolina, USA.
Allan LeveyEmory Goizueta Alzheimer's Disease Research Center, Atlanta, Georgia, USA.
Nathan HerrmannSunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.
Paul B RosenbergDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
TREAT AD Structural Biology CoreU54AG065187 · NIA · EMORY UNIVERSITY · PI ALLAN I LEVEY · 2019 to 2026
$69.7M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI MARILYN S. ALBERT · 2020 to 2026
$29.3M
The Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI Amy D Rodriguez · 2020 to 2026
$29.0M
Wake Forest University School of Medicine Alzheimer's Disease Research CenterP30AG072947 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUZANNE CRAFT · 2021 to 2026
$24.3M
Supplement to AMP-AD Brain Proteomic Network Enhancement, Validation and Translation into CSF BiomarkersU01AG061357 · NIA · EMORY UNIVERSITY · PI LEVEY, ALLAN I, SEYFRIED, NICHOLAS THOMAS · 2018 to 2022
$9.1M
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)R01AG046543 · NIA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HERRMANN, NATHAN, LANCTOT, KRISTA L. · 2014 to 2018
$8.1M
Using connectomics to characterize risk for Alzheimer's DiseaseR01AG055132 · NIA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI JOSEPH, JANE E, MINTZER, JACOBO · 2017 to 2021
$3.7M
NCATS NIH HHS UL1 TR001863NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG072947NIA NIH HHS R01 AG046543NIA NIH HHS R01 AG055132NIA NIH HHS U01 AG061357NIA NIH HHS U54 AG065187
6 · The paper itself

Abstract

objectivesTo examine clinically important adverse events (AEs) associated with methylphenidate (MPH) treatment of apathy in Alzheimer's Disease (AD) versus placebo, including weight loss, vital signs, falls, and insomnia.

methodsThe Apathy in Dementia Methylphenidate Trial 2 (ADMET2) trial was a multicenter randomized, placebo-controlled trial of MPH to treat apathy in individuals with apathy and AD. Participants in ADMET2 had vital signs and weight measured at monthly visits through 6 months. AEs, including insomnia, falls, and cardiovascular events, were reported at every visit by participants and families using a symptom checklist.

resultsThe study included 98 participants in the MPH group and 101 in the placebo group. Participants in the MPH group experienced greater weight loss on average than the placebo through the 6-month follow-up, with a difference in change between MPH and placebo of 2.8 lb (95% confidence interval, CI: 0.7, 4.9 lb). No treatment group differences in change during the trial were found in systolic and diastolic blood pressure. More participants in the MPH group reported falls during the follow-up, 10 versus 6 in MPH and placebo groups, respectively. No differences in post-baseline insomnia were observed between the treatment groups. No participants reported instances of myocardial infarction, congestive heart failure, arrhythmia, stroke, or cardiomyopathy throughout the study period.

conclusionsMPH use in AD patients for treating apathy is relatively safe, particularly notable given the many medical comorbidities in this population. There was a statistically significant but modest weight loss associated with MPH use, and clinicians are thus advised to monitor weight during MPH treatment.

Indexed as

Accidental FallsAlzheimer DiseaseApathyCentral Nervous System StimulantsMethylphenidateWeight LossAgedAged, 80 and overDouble-Blind MethodFemaleHumansMaleSleep Initiation and Maintenance DisordersCentral Nervous System StimulantsMethylphenidateadverse eventsAlzheimer's diseaseapathymethylphenidateweight loss

Identifiers

PMID38858522
PMCPMC11265565

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.